JP Morgan Day 1: Biotech bonanza brings bankers to banquet
This article was originally published in Scrip
Both early- and late-stage drug developers presented pipeline updates to standing room-only crowds of investment managers and high-net worth individuals at JP Morgan's annual gathering for health care-leaning investors in San Francisco on 13 January in light of big returns certain companies provided to investors in 2013.
You may also be interested in...
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.
Despite positive Phase III results in Lennox-Gastaut syndrome, the effect of the company’s low-dose fenfluramine on serious seizures may not be as good as seen with GW Pharma’s Epidiolex.